S-100 protein and LDH have been reported as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies [51]. The gene discussed is CTLA4; the disease is melanoma.